Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$0.39 - $0.54 $3,320 - $4,597
8,514 Added 3.34%
263,328 $126,000
Q1 2023

May 12, 2023

SELL
$0.33 - $0.58 $29,886 - $52,527
-90,565 Reduced 26.22%
254,814 $97,000
Q4 2022

Feb 13, 2023

SELL
$0.33 - $12.0 $78,306 - $2.85 Million
-237,292 Reduced 40.72%
345,379 $113,000
Q3 2022

Nov 14, 2022

SELL
$0.68 - $11.25 $56,123 - $928,507
-82,534 Reduced 12.41%
582,671 $437,000
Q2 2022

Aug 12, 2022

BUY
$0.81 - $3.43 $371,022 - $1.57 Million
458,052 Added 221.12%
665,205 $606,000
Q1 2022

May 13, 2022

SELL
$2.27 - $4.13 $63,846 - $116,160
-28,126 Reduced 11.95%
207,153 $715,000
Q4 2021

Feb 11, 2022

BUY
$3.37 - $6.87 $83,272 - $169,757
24,710 Added 11.73%
235,279 $922,000
Q3 2021

Nov 12, 2021

BUY
$5.78 - $7.86 $1.22 Million - $1.66 Million
210,569 New
210,569 $1.41 Million
Q1 2021

May 13, 2021

SELL
$9.33 - $14.05 $398,978 - $600,820
-42,763 Closed
0 $0
Q4 2020

Feb 10, 2021

SELL
$8.48 - $12.23 $212,983 - $307,168
-25,116 Reduced 37.0%
42,763 $402,000
Q3 2020

Nov 13, 2020

SELL
$9.99 - $14.41 $1.29 Million - $1.86 Million
-129,000 Reduced 65.52%
67,879 $741,000
Q2 2020

Aug 13, 2020

BUY
$12.28 - $17.63 $2.42 Million - $3.47 Million
196,879 New
196,879 $2.72 Million
Q4 2019

Feb 13, 2020

SELL
$6.44 - $14.21 $604,716 - $1.33 Million
-93,900 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$4.6 - $8.46 $57,499 - $105,750
12,500 Added 15.36%
93,900 $619,000
Q2 2019

Aug 12, 2019

BUY
$5.83 - $8.42 $388,861 - $561,614
66,700 Added 453.74%
81,400 $680,000
Q1 2019

May 14, 2019

BUY
$4.02 - $5.81 $59,093 - $85,407
14,700 New
14,700 $85,000

Others Institutions Holding MTEM

About Molecular Templates, Inc.


  • Ticker MTEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,351,600
  • Market Cap $10.1M
  • Description
  • Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developi...
More about MTEM
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.